Risk of renal impairment in atypical antipsychotics: a systematic review and meta-analysis
Document Type
Article
Publication Date
10-1-2024
Abstract
PurposeAtypical antipsychotics are associated with several adverse effects including metabolic syndrome, weight gain, QTc interval prolongation, and extrapyramidal effects. This study aims to investigate the risk of renal impairment in patients receiving atypical antipsychotics.MethodsA systematic literature search was conducted via PubMed and Ovid SP and Web of Science to retrieve studies reporting the risk of renal impairment in patients receiving atypical antipsychotic treatment. The pooled risk ratio (RR) of renal impairment and the subgroup analysis was calculated using the random-effects generic inverse variance method in Cochrane Review Manager.ResultsA total of 4 studies involving 514,710 patients (221, 873 patients on atypical antipsychotics/CKD and 292, 837 controls) were included in this meta-analysis. Patients on atypical antipsychotics exhibited an increased risk of renal impairment, with a pooled risk ratio of 1.34 (95%CI 1.23-1.47). Subgroup analysis demonstrated that atypical antipsychotic use was associated with an increased risk of both acute kidney injury (AKI) (RR 1.51, 95%CI 1.34-1.71) and chronic kidney disease (CKD) (RR: 1.23, 95%CI 1.12-1.35).ConclusionPatients receiving atypical antipsychotics have an increased risk of renal impairment. Quetiapine carries the highest risk of renal impairment encompassing both AKI and CKD.
Keywords
Antipsychotic, Acute kidney injury, Chronic kidney disease, Psychiatric disorders
Divisions
fac_med
Publication Title
European Journal of Clinical Pharmacology
Volume
80
Issue
10
Publisher
Springer
Publisher Location
TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY